• D-Lin-MC3-DMA for Reliable RNA Assays

  2026-09-10

  A scenario-based guide to using D-Lin-MC3-DMA (SKU A8791) in lipid nanoparticle workflows for siRNA and mRNA delivery, with practical guidance for viability, proliferation, and cytotoxicity assays. It connects formulation handling, assay controls, potency interpretation, and vendor selection to published delivery evidence.

• Cy3 Goat Anti-Human IgG: From Mapping to Translation

  2026-09-09

  Antibody discovery is advancing from single-target binding toward cocktails and bispecific formats, but translational value depends on reliable evidence across binding, localization, and function. This article explains how the Cy3 Goat Anti-Human IgG (H+L) Antibody can strengthen human IgG detection workflows supporting orthopoxvirus antibody research while clarifying the reagent’s capabilities and limitations.

• CAMLs in Blood: Phenotype and Clinical Utility

  2026-09-09

  This Cancer Letters study reframes circulating cancer-associated macrophage-like cells, or CAMLs, as phagocytic polyploid giant cancer cells with potential relevance to progression and metastatic niche formation. A prospective, multi-institutional analysis links these abnormal blood cells to disease spread while describing self-renewing, proangiogenic, and mixed myeloid, epithelial, and endothelial features.

• PKM2 inhibitor (compound 3k): Assay Workflows

  2026-09-08

  Build reproducible glycolysis and viability assays around PKM2 inhibitor (compound 3k), from DMSO stock preparation through orthogonal metabolic validation. Its cancer-cell activity and emerging macrophage-metabolism application support distinct workflows for tumor profiling, ovarian cancer therapy research, and mechanism testing.

• WRN–MSI Synthetic Lethality in Colorectal Cancer

  2026-09-08

  This PNAS study explains why mismatch repair-deficient, microsatellite-instable colorectal cancer cells depend on Werner helicase: WRN loss activates a p53–PUMA apoptotic program. Genetic depletion and ML216 treatment suppressed MSI colorectal cancer growth in cell and xenograft models, while p53 or PUMA disruption reduced the effect, providing a mechanistic framework for biomarker-guided WRN-targeted research.

• Thioguanine Workflow for EV71 and Cancer Assays

  2026-09-07

  Build a practical Thioguanine workflow around antiviral, oncology, and epigenetic readouts rather than relying on a single viability endpoint. The approach translates EV71 replication data into controlled dose–response, mechanism-aware assays while addressing solubility, cytotoxicity, and cross-model comparability.

• Firefly Luciferase mRNA: Assay Workflow Guide

  2026-09-07

  Learn how to use Firefly Luciferase mRNA as a sensitive control for delivery, translation, cell viability, and biodistribution studies. This practical guide connects ARCA capping and modified nucleotides with reproducible transfection workflows and emerging mRNA-LNP delivery research.

• Stable Isotope UHPLC–MS/MS for Methylated Purines

  2026-09-05

  The 2024 Analytical Chemistry study developed a stable isotope-diluted UHPLC–ESI-MS/MS workflow for accurate measurement of 12 purine ribonucleosides, including 10 methylated species. Enhanced ionization, chromatographic resolution of methylated isomers, and matrix-reduction steps enabled sensitive intracellular quantification relevant to RNA modification research, cancer metabolism studies, and biomarker discovery.

• (±)-Blebbistatin for Spatial Cell Mechanics

  2026-09-04

  Use (±)-Blebbistatin to reversibly reduce non-muscle myosin II activity while measuring migration, adhesion, and morphology with spatially resolved imaging. Inspired by panoramic cardiac mapping, this workflow links a mechanical perturbation to local cell behavior instead of treating an image as a purely descriptive endpoint.

• YTHDF1–THBS1 Control of Osteogenesis under Hypoxia

  2026-09-04

  The reference study identifies YTHDF1 as a hypoxia-responsive m6A reader that counteracts impaired osteogenic differentiation in MC3T3-E1 cells through post-transcriptional regulation of THBS1. Its combination of gene perturbation, osteogenic phenotyping, and RNA-level analyses provides a mechanistic framework for studying hypoxia-related bone loss in peri-implantitis.

• TEAC: From K+ Pores to Translational Strategy

  2026-09-03

  Tetraethylammonium chloride (TEAC) is more than a broad potassium-channel blocker: it is a mechanistic perturbation tool for connecting pore conduction with cellular, vascular, and translational phenotypes. This article integrates ion-channel biology, evidence from pancreatic beta-cell research, experimental design, product considerations, and strategic guidance for interpreting TEAC-driven results.

• AR Heterogeneity Shapes Castration and Enzalutamide Response

  2026-09-03

  Li and colleagues show that androgen receptor heterogeneity is not merely a descriptive feature of advanced prostate cancer: nuclear, mixed nuclear/cytoplasmic, and AR-low or negative states display different tumor behavior and responses to castration or enzalutamide. By combining patient samples, xenografts, isogenic genome-edited models, RNA sequencing, and combination treatment experiments, the study identifies BCL-2 as a potential vulnerability for AR-low or negative disease.

• HotStart Universal 2X Green qPCR Master Mix

  2026-09-02

  Build reproducible real-time PCR gene expression analysis around a hot-start enzyme, Green I fluorescence, and a universal ROX reference system. This workflow translates a finishing-pig Eucommia ulmoides leaf extract study into practical assay design, from tissue cDNA and dose-response panels to melt-curve verification and troubleshooting.

• Protein A/G Magnetic Beads: Practical IP Guide

  2026-09-02

  Protein A/G Magnetic Beads provide Fc-directed capture for antibody purification, immunoprecipitation, co-immunoprecipitation, and chromatin workflows from complex samples. This guide explains setup, controls, and troubleshooting while defining limits for Fc-lacking antibody fragments, unvalidated assay conditions, and diagnostic or medical use.

• FGFR3 Inhibition in SLC26A2 Chondrodysplasia

  2026-09-01

  The reference study combines genetic models, inducible postnatal deletion, chondrocyte assays, and pharmacological inhibition to show that excessive FGFR3 signaling contributes to SLC26A2-related skeletal dysplasia in mice. Its findings support FGFR3 pathway inhibition as a research direction for improving chondrocyte differentiation, survival, and bone microarchitecture, while leaving human efficacy and dosing questions unresolved.

7931 records 1/529 page Next 12345 下5页 Last page